Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lantern Pharma Inc. shareholders approved Election of six directors to serve until the 2024 Annual Meeting of Stockholders at the 2023-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Election of Directors : All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein, were elected to our board of directors, with shares voted as follows: Name For Withheld Broker Non-Vote Donald Jeff Keyser 3,812,521 443,977 2,805,241 Panna Sharma 4,064,225 192,273 2,805,241 Vijay Chandru 3,810,172 446,326 2,805,241 Maria Maccecchini 3,811,686 444,812 2,805,241 Franklyn Prendergast 4,048,745 207,753 2,805,241 David S. Silberstein 4,060,996 195,502 2,805,241
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lantern Pharma Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Ratification of Independent Registered Public Accounting Firm : In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, with shares voted as follows: For 7,015,460 Against 41,115 Abstain 5,164 There were no broker non-votes on the ratification of our independent registered public accounting firm.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lantern Pharma Inc. shareholders approved Approval of an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan to increase the number of shares available for issuance by an additional 250,000 shares at the 2023-06-16 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Amendment to Equity Incentive Plan : Our stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares, with shares voted as follows: For 4,145,520 Against 96,840 Abstain 14,138 Broker Non-Votes 2,805,241
View on SEC.gov